Recently, it was demonstrated that in a real-world population of HR+/HER2− advanced breast cancer patients receiving CDK4/6i plus ET in the first line, the proliferative index marker Ki67 was significantly inversely correlated with PFS, suggesting that this may be a marker of CDK4/6i resistance (26). The gene discussed is CDK4; the disease is breast carcinoma.